Geisinger, Merck collaborate for patient adherence

Geisinger Health System and pharmaceutical company Merck will enter into a new multi-year collaboration designed to improve patient health outcomes by focusing on shared decision making between patients and physicians and improved patient adherence.

Teams from Danville, Pa.-based Geisinger and Whitehouse Station, N.J.-based Merck will work together to improve patient adherence, increase the role of patients in making decisions to help manage their conditions, share information among extended care teams and improve clinical care processes, according to a statement from the organizations.

The first tool being developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome, a clustering of various risk factors that puts an individual at risk of developing type 2 diabetes and cardiovascular disease.

The web application and other care management tools Merck and Geisinger develop will initially be tested within the Geisinger system, they added. 

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup